Omeros (OMER) Stock Price, News & Analysis

Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $4.00 to $4.70
• 50-Day Range: $3.80 to $9.16
• 52-Week Range: $3.00 to $13.60
• Volume: 2.29 million shs
• Average Volume: 625,746 shs
• Market Capitalization: $269.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Moderate Buy

Omeros Stock Analysis - MarketRank™

Omeros scored higher than 77% of companies evaluated by MarketBeat, and ranked 301st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omeros has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Omeros has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omeros are expected to grow in the coming year, from ($3.09) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omeros is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omeros is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.46% of the float of Omeros has been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Omeros has recently decreased by 14.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omeros does not currently pay a dividend.

Dividend Growth

Omeros does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.30

Percentage of Shares Shorted

16.46% of the float of Omeros has been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Omeros has recently decreased by 14.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.41

News Sentiment

Omeros has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Omeros this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for OMER on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omeros insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.30% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMER Stock Analysis - Frequently Asked Questions

How have OMER shares performed this year?

Omeros' stock was trading at $9.88 on January 1st, 2025. Since then, OMER shares have decreased by 55.4% and is now trading at $4.41.
View the best growth stocks for 2025 here.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) released its quarterly earnings results on Monday, March, 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08.
Read the conference call transcript.

Does Omeros have any subsidiaries?

Omeros subsidiaries include these companies: Nura.

Who are Omeros' major shareholders?

Top institutional shareholders of Omeros include Vanguard Group Inc. (5.55%), Charles Schwab Investment Management Inc. (0.80%), Bank of New York Mellon Corp (0.26%) and Nuveen LLC (0.20%). Insiders that own company stock include Peter A Md Demopulos, Gregory A Md Demopulos and Arnold C Hanish.
View institutional ownership trends.

How do I buy shares of Omeros?

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Omeros own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Omeros investors own include JPMorgan Chase & Co. (JPM), Visa (V), AbbVie (ABBV), Meta Platforms (META), NVIDIA (NVDA), QUALCOMM (QCOM) and Global X Nasdaq 100 Covered Call ETF (QYLD).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 5/13/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OMER
• CIK: 1285819
• Web: www.omeros.com
• Phone: (206) 676-5000
• Fax: 206-676-5005
• Employees: 210
• Year Founded: 1994

Price Target and Rating

• Average Stock Price Target: $22.50
• High Stock Price Target: $36.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +394.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-117,810,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -49.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.96
• Quick Ratio: 2.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.40) per share
• Price / Book: -11.38

Miscellaneous

• Outstanding Shares: 58,306,000
• Free Float: 50,822,000
• Market Cap: $265.29 million
• Optionable: Optionable
• Beta: 2.42